– the leading provider of online annual reports to individual and institutional investors.

Telik Inc.

Telik, Inc., a clinical-stage drug development company, engages in the discovery and development of small molecule drugs to treat cancer. Its product candidates in clinical development stage include TELINTRA, a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 or GST P1-1 for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia; and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer.

View Online Reports:
No investor fact sheets added yet
No responsibility reports added yet

Browse Reports